A prior or dominant immunization of mice with one antigen abolished CD8 § cytolytic T lymphocyte (CTL) 1 responses to a second unrelated antigen given simultaneously (1) . Suppression became systemic and could be transferred passively to normal mice by fresh immune serum alone. In the present experiments, fresh serum from such immunized mice in high dilution abolished CTL responses in one-way MLC, presumably in a way analogous to that occurring in vivo. The following experiments were designed to determine the nature of the serum components and the cells responsible for suppression of CTL in MLC.
Materials and Methods
Mice and Cell Lines. Donors of sera and lymphoid cells were C3H (H2 k) female mouse mammary tumor virus-negative (MTV-) pathogen-free mice 8-12 wk old and housed in a bartier facility; donors of allogeneic cells were BALB/C (H2 b) female mice also pathogen free and housed in a barrier facility. C3H SCID mice purchased from Imdyne (San Diego, CA) were Pneumocystis 1Abbreviations used in this paper: AD -, nonadherent cells; otSer, sera from immune mice; CTL, cytolytic T lymphocytes; DC, dendritic cells; HRBC, horse red blood cells; Mqt, macrophages; NMS, normal mouse serum.
carinii free and housed similarly. Tumor targets for measuring CTL in MLC were P815 (H-2 d) calls (see accompanying manuscript [1] for details).
Immunizations and Murine Sera. C3H mice under light ether anesthesia were injected in hind foot pads with 0.05 ml of 5% (vol cells/vol diluent) cell suspension of washed sheep or horse erythrocytes (SRBC or HRBC); injections were repeated every other day four to six times; mice were bled 1 or 2 d after the last injection; i.e., 7-12 d after injections began. Sera from immune mice (c~Ser) were pooled from three or four identically injected mice and used within 72 h unless noted otherwise. Normal mouse sera (NMS) were obtained from nonimmunized mice of the same age and housed identically. NMS and c~Ser were either untreated ( Table 1 , Exps. 1 and 2) or diluted 1:10 in RPMI and separated into <100-and >100-kD fractions by fihration/centrifugation using Centricon Microconcentrators (Amicon, Beverly, MA) for Exp. 3 (Table 1) and all subsequent experiments. Both the <100-and >100-kD fractions were reconstituted to the same volume as the sample before fractionation and were considered to be at a dilution of 1:10. Lymphocytes, Nonadherent Cells (Ad-), Dendritic Cells, and Cells without Macrophages, Popliteal lymph node or spleen cells were dispersed and washed in complete medium; debris and aggregates were removed by gravity sedimentation. Ad-were incubated twice for 60 min with carbonyl iron (10 s ceils/10 ml medium/2 grn carbonyl iron); ,,o95% of macrophages (M~) and dendritic ceils (DC) are removed by this procedure. Cells highly enriched for DC were obtained from cells that adhere to plastic culture plates (105 cells/10 ml medium/10-cm culture plates) in an initial 2-h incubation; nonadherent cells were removed and the volume restored. Most DC detach during an additional 18-22-h incubation while most Mq~ remain adherent; ,~2 x 105 detached cells are usually recovered per 10 s spleen cells and 60-80% of these cells are DC with most of the contaminating cells consisting of M~k. Ad-cells do not respond in MLC unless restored by adding DC, •3 x 104 DC/5 x 105 responding lymphocytes being optimal.
MLC and Assay.for Cytolytic T Cells. MLC were 5 x 105 C3H (H2 k) normal spleen cells and 5 x 105 normal, irradiated (2,000 rad) BALB/c (H2 a) spleen cells per well of 96-well flat-bottomed tissue culture plates (2). Cells were suspended in 100/~1 of complete medium, which was: RPMI 1640 with 25 mM Hepes supplemented with 2 mM t-glutamine, I mM sodium pyruvate, 0.1 mM nonessential amino acids, 5 x 10 -s M 2-ME, and 10% FCS; 50 U penicillin and 50/zg of streptomycin were added per 100 ml of medium. 100/xl of supplemented RPMI 1640 without FCS was added to each culture; this addition was either medium alone for control cultures or contained agents such as IgGs, TGF4~, etc. Thus, the final concentration of FCS was 5%, and concentrations or dilutions of each additional agent are recorded per milliliter of the final 200/xl of culture medium. Cultures were incubated 4 or 5 d at 37~ 5% CO2, and 100% humidity. Controls were six or eight replicate cultures to which medium alone was added; each variable was tested in duplicate or triplicate cultures. Viable cell recovery was equivalent (less than twofold difference) in control and variously treated cultures. One-half of each culture (E/T cell ratio of ,~50:1) and seven additional double dilutions of each culture were assayed separately against SlCr-labeled P815 (H2 a) target cells using 4-h SlCr release assay (2); each culture was assayed separately so that results are means for six to eight cultures containing medium only and two or three cultures for each variable tested. For convenience for comparing control and variously treated cultures, results are reported for only three fourfold dilutions or fractions of cultures assayed. Because the slopes of curves for lysis caused by different dilutions of cells from test and control cultures are rarely parallel, we have no adequate way for statistical analysis of differences. Also, for this reason, it is not strictly appropriate to convert results to lytic units, although we have done this to make comparing gross differences easier. For this purpose, a lytic unit is arbitrarily defined as the reciprocal of the fraction of identical cultures, rounded to the nearest 10, causing 30% lysis of labeled target cells. We only emphasize differences between test and control cultures greater than fourfold whether indicated by comparing lysis at different fractions of culture or by lytic units. Furthermore, all of the differences of this magnitude reported have been confirmed in two or more additional experiments, which are not reported. Treating responder cells before culture or treating cells harvested from MLC after 4 or 5 d incubation with anti-CD8 antibody and complement abolishes CTL activated in this culture system (2).
Secretion and Assay for TGF-fl. Lymphoid cells or a murine cell line designated 7.63, originally designated 1591-N-TGF-1, transfected to secrete murine latent TGF-/81 (3) were cultured in 5 x 105 cells/ml of MEM containing 0.1% FCS at 37~ 7.5% COs, and 100% humidity for 48 h. The medium alone contained <0.01 ng active and <0.1 ng total TGF-B/ml. Supernatants were assayed without treatment to measure active TGF-B, and after acidification at pH 2.0 for 30 min, to measure total TGF-B. Secretion is recorded as ng/105 cells per 24 h using an assay dependent on inhibition of proliferation of cells from a line of mink lung "epithelial-like" cells, designated MvlLu (4). TGF-B is secreted as a latent complex of "~110 kD; only the cleaved active 25-kD homodimer binds receptors or is bound by the anti-TGF-3 antibodies we have. The assay does not discriminate between different isoforms of TGF-B, but neutralization of suppression by antibodies to TGF-/~ confirms that suppression is mediated by TGF-/~, and antibodies relatively specific for different isoforms can indicate the form of active TGFin a preparation using the MvlLu assay.
Antibody Titers. Sera were serially double diluted in PBS containing 0.5% BSA in 96-well V-bottomed plates. For agglutinin titers, each well contained 50/~1 of diluted serum and 50 #1 of 0.05% RBC; for hemolysin titers, each well contained an additional 50 /zl guinea pig complement absorbed with SRBC and HRBC and diluted 1:20 in PBS; each sample was titered in duplicate for both agglutinin and hemolysin titers. Plates were incubated I h at 37~ and overnight at 5~ Titers were read using a magnification of 3. The antibody titers are reported as the reciprocal of the highest serum dilution that caused gross agglutination or complete hemolysis of erythrocytes; duplicate titers did not vary more than one double dilution. Hemolysin titers are not reported separately but were equal to or one double dilution lower than agglutinin titers.
Reagents. Murine The supranatants obtained after centrifugation and filtration were dialyzed against medium overnight. For absorption on heterologous erythrocytes, sera were diluted 1:25 in medium and absorbed (vol/vol) with packed erythrocytes for 10 min at 5~ with frequent mixing. The supranatant was obtained by centrifugat;.'on and the procedure was repeated.
Results

Immune Sera Abolish CTL Responses in MLC.
We observed repeatedly that fresh NMS added to MLC at final dilution in culture of 1:50-100 had no significant effect on CTL responses; in contrast, fresh immune sera (ctSer) at these or higher dilutions abolished CTL responses. In different experiments otSer were from: (a) mice bearing immunogenic tumors that had grown for 2 or 3 wk or were from mice that had recently rejected such tumors; or (b) mice bled 1-3 d after receiving three or more injections of allogeneic spleen cells or xenogeneic erythrocytes given every 2 or 3 d. These observations were confirmed in a single experiment ( Table  1 , Exp. 1). We found repeatedly, as in Table 1 , Exp. 1, that uSer raised against xenogeneic erythrocytes were usually suppressive at higher dilutions than were sera from mice immunized by tumors or aUogeneic spleen cells. Partially for this reason, but also for convenience for presenting data, we report in the following experiments only results using sera from C3H mice immunized with xenogeneic erythrocytes, though the essential findings have been confirmed using sera from C3H mice immunized in these other ways and sera from two other strains of mice immunized with xenogeneic erythrocytes.
Blood was as suppressive as serum (Table 1, Exp. 2), indicating that the process of clotting does not activate or generate factors responsible for suppression. For this experiment, 0.1 ml of heart blood from a single normal or immune (five injections of SRBC) mouse was added directly to 4.9 ml of culture medium and cells were immediately removed by centrifugation. Serum was prepared from the remaining heart blood obtained from the same mice after allowing clot retraction to occur at room temperature for 90 min. The experiment included blood and sera from a mouse injected identi- In a single trial all suppressive activity of an aSer fractionated by gel filtration was recovered in fractions of >70 kD. In repeated trials all suppressive activity of different pools of o~Ser was recovered in the >100-kD fraction obtained by filtration/centrifugation (Table 1, Exp. 4), and as in that experiment the <100-kD fraction usually stimulated responses two-to fourfold. To reduce complications caused by components in sera that may have contrary effects in MLC, all sera for the following experiments were separated by filtration/centrifugation and only the >100-kD fractions were used, except as noted.
We observed repeatedly that sera from mice injected with antigen five or six times were more suppressive than sera from mice injected three or four times, and that suppressive activity of sera was often lost or decreased by more than a threefold dilution when stored for I wk or more at 5 or -20~ though we have not assessed these variables systematically.
To avoid such problems czSer were used within 48 h of bleeding in each of the following experiments, and each serum tested was the >100-kD fraction of serum pooled from three or more mice injected five or six times with xenogeneic erythrocytes and bled I or 2 d after the last injection. We have found subsequently that the >100-kD fraction of c~Ser stored at -80~ retains full suppressive activity for at least 6 wk. In each of the following experiments, aSer and each of the variables were tested at two or usually three threefold serial dilutions; we report results for only the highest serum dilution, which caused >~10-fold suppression of CTL responses.
IgG Specific for the Immunizing Antigen Causes Suppression. As shown in Table 2 , Exps. 1 and 2, crSer absorbed on protein A, protein G, or goat anti-murine Ig coupled to Sepharose no longer caused suppression. Protein A and protein G bind predominantly IgG whereas the goat anti-routine Ig should remove all isotypes. Indeed, considerable anti-SRBC antibody (IgM and IgA identified by ELISA; data not presented) remained after absorption on protein A or protein G, but not after absorption on the goat anti-murine Ig. In recently completed experiments, absorption of aSer on goat anti-murine IgG coupled to Sepharose was as effective in removing all suppressive activity as absorption on goat anti-murine Ig (IgM, G, A), though absorption on c~IgG did not remove all specific anti-RBC antibody, whereas absorption on cdg did. Absorption of o~Ser on goat anti-murine IgM coupled to Sepharose reduced antibody titers four- Together, the results indicated that suppression was mediated by IgG. Table 2 , Exps. 3 and 4, show that Ig directed against the antigen used to raise the immune serum was responsible for suppression; i.e., otSer raised against SRBC lost all specific antibody activity and all suppressive activity after absorption on SRBC but not after absorption on HRBC; similarly, o~Ser raised against HRBC lost all specific antibody activity and nearly all suppressive activity after absorption on HRBC but not after absorption on SRBC.
Antibodies against TGF-~ Prevent Suppression. Nonantigenspecific, non-H2-restricted suppression caused by ctSer mimicked suppression caused by active TGF-~ in several ways. Addition of 1.0-10.0 ng active pTGF-B1 or mTGF-~I to MLC powerfully suppressed CTL responses. Addition of this amount or 10x more latent mTGF-~8 had no effect on CTL responses. Maximum suppression occurred when otSer or active TGFt8 was added to MI.C during the first 24 h of culture; no suppression occurred when either agent was added on days 3 or 4 of culture. Also, both agents caused little or no suppression of CTL responses using sensitized cells obtained from mice recently immunized with the same alloantigen as used in the MLC.
To test directly whether TGF-B might be involved, antibodies to TGF-B were added to MLC. In repeated experiments a routine mAb against TGF-/~ 2,3 (IgG2b) at concentrations that partially neutralized the effects of 1.0-3.0 ng of active porcine or murine TGF-~8 prevented suppression caused by adding c~Ser to MLC (e.g., Table 3 , Exp. 1). Control IgG2b of unknown specificity added to cultures at the same or 3 x the concentration of the anti-TGF-B antibody had no effect on CTL responses. Also, in repeated experiments, a chicken antibody against TGF-/31 at concentrations that neutralized 1.0-3.0 ng of porcine or routine TGF-~8 in MLC very effectively prevented suppression caused by c~Ser, (e.g., Table 3 , Exp. 2). The chicken antibody against TGF-/3 alone had no effect on CTL responses in MLC; however, the findings using chicken antibody have to be taken with reservation (and serve as a cautionary note) because the normal chicken Ig provided as a control caused bizarre effects on cells in MLC that we have not observed for the chicken antibody against TGF-~ or for any other additive we have ever used during the course of a great many experiments.
Secretion of TGF-fl by Lymphocyte& otSer might suppress CTL responses by stimulating ceUs in MLC to secrete TGF-B.
For these experiments, secretion of TGF-B by lymphoid cells was compared with secretion by a routine cell line transfected Table 4 . Lymphocytes, including B cells, secrete significant amounts of latent TGF-~, and cells from normal mice secrete as much TGF-~ as cells from immune mice. Furthermore, normal sera were as effective as o~Ser in stimulating secretion of TGF-B. In other experiments (data not presented), Table 4 . sera from SCID mice or olSer absorbed on protein G were also as effective as normal or immune sera. Thus, it is unlikely that suppression of CTL caused by adding c~Ser to MLC is secondary to stimulation of secretion of TGF-/~ by responding cells. For this reason, we examined whether IgG in o~Ser might carry TGF-B.
Secretion of TGF-B by Lymphocytes
TGF-~ Is Associated with or Carried by IgG. Different in-
dividual or pooled NMS or o~Ser contained "~200-300 ng TGF-/3/ml; >90% of serum TGF-B was latent and >90% of acid activated TGF-B in sera was neutralized by antibody to TGF-BI. We found no consistent differences in total amounts of latent or active TGF-~ in either whole or the >100-kD fractions of NMS or c~Ser. Absorptions to remove Ig from NMS or aSer consistently reduced serum concentrations of TGF-~ by •25-50%. The findings indicated that "~2.0-10.0 ng of TGF-B is carried per 1.0 mg IgG (assuming that serum contains '~20 mg IgG/ml of serum), and each of two commercial preparations of mlgG affinity purified from "normal" mouse sera did contain 3-5 ng latent TGF-B/mg IgG ( Table 5 ). Neither of the commercial preparations at a concentration of 1.0 mg IgG/ml culture medium inhibited (or enhanced) CTL responses. We then purified IgG from our NMS and o~Ser by absorption on protein G coupled to Sepharose, washing the column contents with 10 vol of diluent, pH 7.0, and briefly eluating absorbed IgG at pH 2.7 for 1.5 min using a 1.0 M glycine-HC1 buffer. The neutralized eluate from NMS contained no measurable active TGF-fl and '~5.0 ng latent TGF-~/mg IgG, which caused no suppression when added to MLC at 1.0 mg IgG/ml of culture medium. In marked contrast, the eluate from olSer, containing '~1.0 ng active and *30.0 ng latent TGF-B/mg IgG, abolished CTL responses at a dilution that added "~3.0 /~g IgG and '~0.1 ng TGF-/5/ml of culture medium ( 
IgG Dissociated from TGF-fl No Longer Causes Suppression.
While IgG in olSer carried significant amounts of latent TGF-B, suppression by c~Ser appeared to be an order of magnitude greater than could be accounted for if all the carried TGF-~ was activated. Indeed, o~Ser acidified at pH 2.0 for 30 min no longer suppressed CTL responses at the same high serum dilution, though acid-treated c~Ser at low dilutions that added 1.0-3.0 ng of the activated TGF-fl/ml of culture medium did suppress, and this suppression was prevented by preincubation of the treated sera with antibody to TGF-~ (data not presented).
Acid treatment of olSer not only activated TGF-/~ but also dissociated it from IgG. This was shown by acidifying o~Ser and fractionating it before neutralization. This procedure yielded all specific olSRBC or olHRBC antibody in the >100-kD fraction and all TGF-3 in the active form and in the <100-kD fraction. The acidification/fractionation procedure did not cause any loss of complement-dependent hemolytic activity, which requires the Fc portion of antibody molecules. Interestingly, fractionation of c~Ser after acidification and neutralization yielded the same amounts of active TGF-3, but virtually all of the TGF-B was now recovered in the >100-kD fractions, indicating that the activated TGF-/3 reaggregates possibly with itself and/or other large molecules. These findings for one experiment are shown in Table 6 . Aliquots of olSer were either acidified for 30 min and fractionated before neutralization or were treated with the same quantities of acid and base added simultaneously before fractionation. The >100-kD fractions of both samples had the same antibody titers to SRBC but the >100-kD fraction of the acidtreated aliquot no longer suppressed effectively whereas the control aliquot did, suggesting that the combination of IgG and TGF-B in fresh immune serum may have to be in a particular or unique configuration for suppression to occur.
Macrophages Are Obligatory for Suppression
Caused by Immune Serum. Two call types are obligatory for CD8 + CTL responses in MLC, CD8 + lymphocytes, and DC (5). Selective removal in vitro of B lymphocytes, or in vivo of CD4 + lymphocytes or NK cells from populations of responder and irradiated stimulator cells, did not lower (and usually caused higher) CTL responses, and in each case c~Ser was fully suppressive (data not shown). In contrast, o~Ser caused no suppression in Ad-cultures but reconstituted with DC (Ad-+ DC) ( Table 7 , Exp. I), though small quantities of active pTGF-~ abolished responses in such cultures (Table 7 , Exp.
2). These findings were confirmed in similar experiments using different o~Ser and active mTGF-/~ as well as pTGF-B. IgG-TGF-B might stimulate M0 to secrete factors, including leukotrienes, prostaglandins, nitric oxide, or cytokines, that could suppress lymphocyte function, but in an extensive series of experiments we were unable to prevent suppression caused by otSer with indomethacin, acetylsalicylic acid, N-monoethyl-t-arginine, TNF-c~, IL-2, or selected other cytokines, each tested at six concentrations over a 2-log range (data not shown).
Interference with MO Function Prevents Suppression by Immune
Sera. Presumably M0 take up IgG-TGF-B via Fc receptors for IgG and, as shown in Table 8 , Exp. 1, a rat antibody directed against murine Fc receptors partially prevented suppression by otSer. Also, rabbit IgG added to cultures prevented suppression by aSer in a dose-dependent manner ( * The dilution of (xSer was 1:300. * Acidification was at pH 2.0 for 30 rain with fractionation done before neutralization; control o~Ser was treatM with the same quantity of acid and base added simultaneously before fractionation. Results are for the >100 kD fraction. $ Fraction of culture. 
Discussion
Fresh homologous sera are often "toxic" for many culture systems; the fact that our sera came from pathogen-free mice may account for why 1-2% NMS did not suppress cultures and allowed us to study components in immune serum that do suppress CTL responses. Though our immune sera were obtained from intensely immunized mice, immunization was meant to be comparable to the antigenic challenge that might occur with growing tumors or infectious agents. Adjuvants were not used and all of our sera were obtained within 6-12 d of the first injection of antigen; thus, we do not think our results are an artifact of an unphysiological regime for immunization. Though we have not studied the variables of antigen dose or injection schedule systematically, we have observed that serum obtained 7 d after a single injection of antigen was much less suppressive than sera from mice receiving the same total dose of antigen given every 2 d for three injections.
Repeated antigen injections should favor formation of circulating antigen-antibody complexes that are taken up by MO and can cause various immunologic effects (7) (8) (9) . Our c~Ser may well contain complexes present in great antibody excess and such complexes could play a role, though we have been unable to reproduce suppression with complexes formed in vitro over broad ranges of antigen-to-antibody ratios using various purified specific antibodies and appropriate soluble or particulate antigens. Also, heat-aggregated IgGs, which reproduce many of the effects of complexes, did not cause suppression of CTL responses, and storage of sera that favors aggregation of IgGs caused immune sera to lose rather than gain suppressive activity. IgGs are dissociated from antigens and other ligands by acidification; brief acid elution of IgGs from fresh immune sera absorbed on protein A or protein G yielded duates that were fully suppressive. Acidification, pH 2.0 for 30 min should be more effective in dissociating antigen-antibody complozs, but this procedure also dissociates Ig and TGF-B, which may be the more critical effect of acid treatment. These arguments are supported by recent preliminary observations that indicate that suppression can be mediated by a <300-kD fraction of o~Ser that would exclude antigen-antibody complexes formed in great antibody excess, but the findings obtained to date do not rule out that suppression can be caused by a >300-kD fraction of c~Ser.
Our interest in the role of TGF-~ originally arose because active TGF-~ suppresses activation and proliferation of resting lymphocytes (10) (11) (12) (13) (14) ; glioblastomas and selected other tumors secrete latent TGF-~ and are associated with immune suppression (15) (16) (17) , and an immunogenic murine tumor transfected to secrete latent mTGF-/~ failed to stimulate CTL in vivo and in vitro (3) . Though the experiments presented here do not prove that TGF-B carried by IgG in c~Ser is responsible for suppression of CTL responses, we think the inference is strong and the concept important enough to be considered until confirmed or refuted.
Ongoing studies are designed to determine whether suppression by otSer is caused by a particular subclass of IgG and whether IgG and TGF-B are secreted as a complex or combine after secretion. Latent TGF-B of--110 kD is cleaved to yield the active 25-kD homodimer but the physiological process for activating TGF-B is not understood, though it is accomplished in the laboratory with various proteolytic enzymes (18) and most usually by acidification. This procedure requires pH 2.0 for >15 min; relatively little active TGF-/3 is obtained at higher pH or during shorter periods of acidification. The inactive portion of latent TGF-~ has at least three glycosylation sites that are necessary for latency (19) ; thus, it is tempting to think that IgG and TGF-B may be linked through carbohydrate chains that are cleaved or digested at target sites, e.g., by Mc#, causing activation of the carried TGF-~. Possibly the structure of the linkage between TGF-B-IgG in fresh serum may alter on storage or manipulation to account for the lability of suppressive activity of otSer, since the total amount of assayable TGF-/3 in otSer remains stable during storage.
Since IgGs and latent TGF-B are of comparable molecular mass, only a very small fraction of IgG molecules in olSer must carry TGF-B. However, even a few nanograms of TGF-B per milligram of IgG has the potential for producing important biological effects if TGF-B can be delivered, concentrated, and activated at precise sites. M~k focusing the activity of TGF-B delivered by IgG through Fc receptors may explain why TGF-/3 associated with IgG is an order of magnitude more effective in suppressing CTL responses than free active TGF4t added to cultures, and may account for difficulties using antibodies against TGF-/3. Antibodies to TGF-/3 neutralize only active TGF-~ and are effective in bioassays only when they are preincubated with active TGF-/3 before addition to target cells because of the higher affinity of active TGF-/~ for receptors than for antibody. Thus, in MLC, antibodies to TGF-~ may have different access to TGF-/3 in the cell-cell interaction or diffusion-limited space between MO and lymphocytes depending on the form of the antibody. For example, this may explain why a murine mAb against TGF-B1,2,3 (subclass IgG1) does not prevent suppression (data not presented), whereas a murine mAb against TGF-B2,3 (subclass IgG2b) does (Table 3) . Possibly the subclass of antibody against TGF-B may be more critical than the epitope on
TGF-.
We have confirmed that the mAb against TGFB2,3 does not neutralize m or pTGF-~I in the MvlLu bioassay; however, the same antibody does partially neutralize suppression of CTL responses in MLC caused by pTGF-B1 or c~Ser ( Table  3 ). The different isoforms of TGF-B undoubtedly share epitopes, and receptors for TGF-B are probably not identical on MvlLu cells and murine lymphocytes. For these reasons, we do not think it surprising that an antibody that neutralizes the interaction of one isoform of TGF-B with receptors on cells in one system will necessarily be effective in another system and vice versa. Different considerations limit the use of other antibodies against TGF-B in MLC. For example, we cannot use rabbit antibodies because control rabbit IgG is as effective as rabbit anti-TGF-B antibody in preventing suppression by otSer, undoubtedly because rabbit IgG blocks or saturates Fc receptors. Nevertheless, we interpret our overall findings as consistent with the idea that suppression caused by o~Ser is mediated by TGF-B1.
On a broader scale, the effects of TGF-3 are pleiotropic and depend on the type and state of activation or maturation of target cells in many different tissues (20) (21) (22) (23) (24) , suggesting that the activity of TGF-fl must be highly restricted or regulated at different sites. Thus, the idea that the activity of TGF-fl in immunity is modulated by Ig suggests one kind of strategy for limiting the activity of TGF-fl to the relevant system, just as the association of TGF-fl-2 with c~-fetal protein (25, 26) suggests a different strategy for limiting activity of TGF-fl to the site of maternal-fetal interaction. Thus, IgG localizing TGF-fl at antigenic sites could play an important role in the homeostasis of immunity by augmenting proliferation of already activated dominant lymphocyte clones (27) , promoting isotype switch (27) (28) (29) , suppressing activation/proliferation of new specific antigen-reactive clones that may arise during ongoing immunity, and suppressing some autoimmune diseases (30) . On the other hand, TGF-fl can promote abnormal scarring as well as wound healing (31) (32) (33) (34) (35) (36) (37) , and stimulate growth of some malignancies (38) (39) (40) (41) , so that antibody carrying TGF-fl to antigen target sites in some autoimmune diseases or cancer may have deleterious effects. In an analogous way, desirable or adverse effects of specific antibodies given passively for experimental or clinical objectives (42) may depend on the presence and nature of TGF-fl carried by IgG. Thus, the finding that IgG can carry biologically effective TGF-fl has many important implications.
This work was supported by grants from the National Institutes of Health (R37 AI-10242 and RO1-2267).
